Results 21 to 30 of about 746,277 (164)
Journal for ImmunoTherapy of Cancer, 2019 Background Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells.
Luciana Molinero +9 more
doaj +1 more source
Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program [PDF]
, 2017 Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's ...
Albin, Roger +25 more
core +1 more source
Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations [PDF]
arXiv, 2023 During drug development, evidence can emerge to suggest a treatment is more effective in a specific patient subgroup. Whilst early trials may be conducted in biomarker-mixed populations, later trials are more likely to enrol biomarker-positive patients alone, thus leading to trials of the same treatment investigated in different populations.
arxiv
Frontiers in Molecular Biosciences, 2022 NaPi2b is a sodium-dependent phosphate transporter that belongs to the SLC34 family of transporters which is mainly responsible for phosphate homeostasis in humans.
Leisan Bulatova +8 more
doaj +1 more source
Experimental Hematology & Oncology, 2021 We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later experienced disease progression.
Yulei Wang +6 more
doaj +1 more source
Characterization of Cancer/Testis Antigens as Prognostic Markers of Ovarian Cancer
Diagnostics, 2023 The main goal of this study was to characterize cancer/testis antigens (CTAs) as potential molecular markers of ovarian cancer. First, we gathered and analyzed a significantly large dataset of 21 selected CTAs that are encoded by 32 genes; the dataset ...
Ramilia Vlasenkova +3 more
doaj +1 more source
Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C [PDF]
, 2015 Hepatitis C virus (HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma (HCC), one of the most common fatal cancers worldwide - fourth for ...
Fassina, Giorgio +3 more
core +1 more source
Decision Tree for Protein Biomarker Selection for Clinical Applications [PDF]
arXiv, 2023 Discovery of novel protein biomarkers for clinical applications is an active research field across a manifold of diseases. Despite some successes and progress, the biomarker development pipeline still frequently ends in failure as biomarker candidates cannot be validated or translated to immunoassays.
arxiv
How shall we use the proteomics toolbox for biomarker discovery? [PDF]
, 2007 Biomarker discovery for clinical purposes is one of the major areas in which proteomics is used. However, despite considerable effort, the successes have been relatively scarce.
Hochstrasser, Denis +2 more
core +5 more sources
Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso [PDF]
arXiv, 2022 In clinical trials, identification of prognostic and predictive biomarkers is essential to precision medicine. Prognostic biomarkers can be useful for the prevention of the occurrence of the disease, and predictive biomarkers can be used to identify patients with potential benefit from the treatment.
arxiv